Optimizing Treatment of V600E-Mutant Metastatic NSCLC With Encorafenib and Binimetinib: A Practical Resource for Advanced Practice Providers

Overview

Journal J Adv Pract Oncol

Date 2025 Jan 13

PMID 39802524

Authors

Kelly Goodwin

Kristi Orbaugh

Kirsten Duncan

Erica Stumpf

Affiliations

Soon will be listed here.

Abstract

The V600E mutation aberrantly activates the mitogen-activated protein kinase (MAPK) pathway, subsequently resulting in uncontrolled cellular proliferation, survival, and dedifferentiation. Approximately 2% of patients with non-small cell lung cancer (NSCLC) have a V600E mutation. BRAF and MEK inhibitor combination therapy targets two kinases within the MAPK pathway. Encorafenib (Braftovi) and binimetinib (Mektovi) are potent oral inhibitors of BRAF and MEK, respectively. With the recent US Food and Drug Administration approval of encorafenib plus binimetinib, adult patients with V600E-mutated metastatic NSCLC have an additional treatment option. In the phase II PHAROS study, encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee and exhibited a manageable safety profile in this patient population. This article provides an overview of the efficacy and safety of encorafenib plus binimetinib and uses a fictional patient case to illustrate the role of advanced practice providers in providing individualized patient care and identifying and managing adverse reactions.

References

Owsley J, Stein M, Porter J, In G, Salem M, ODay S . Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood). 2020; 246(1):31-39. PMC: 7797994. DOI: 10.1177/1535370220959657. View

Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A . Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011; 29(26):3574-9. DOI: 10.1200/JCO.2011.35.9638. View

Guisier F, Dubos-Arvis C, Vinas F, Doubre H, Ricordel C, Ropert S . Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. J Thorac Oncol. 2020; 15(4):628-636. DOI: 10.1016/j.jtho.2019.12.129. View

Dagogo-Jack I, Martinez P, Yeap B, Ambrogio C, Ferris L, Lydon C . Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. Clin Cancer Res. 2018; 25(1):158-165. DOI: 10.1158/1078-0432.CCR-18-2062. View

Hendriks L, Kerr K, Menis J, Mok T, Nestle U, Passaro A . Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4):339-357. DOI: 10.1016/j.annonc.2022.12.009. View

Planchard D, Besse B, Groen H, Hashemi S, Mazieres J, Kim T . Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. J Thorac Oncol. 2021; 17(1):103-115. DOI: 10.1016/j.jtho.2021.08.011. View

Pai-Scherf L, Blumenthal G, Li H, Subramaniam S, Mishra-Kalyani P, He K . FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017; 22(11):1392-1399. PMC: 5679831. DOI: 10.1634/theoncologist.2017-0078. View

Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A . BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. J Thorac Oncol. 2018; 13(8):1128-1137. DOI: 10.1016/j.jtho.2018.04.024. View

Hsu K, Tseng J, Yang T, Chen K, Su K, Yu S . PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep. 2022; 12(1):9753. PMC: 9192769. DOI: 10.1038/s41598-022-13102-7. View

10.

Sheikine Y, Pavlick D, Klempner S, Trabucco S, Chung J, Rosenzweig M . in Lung Cancers: Analysis of Patient Cases Reveals Recurrent Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precis Oncol. 2020; 2. PMC: 7446447. DOI: 10.1200/PO.17.00172. View

11.

Tran B, Cohen M . The discovery and development of binimetinib for the treatment of melanoma. Expert Opin Drug Discov. 2020; 15(7):745-754. PMC: 7539481. DOI: 10.1080/17460441.2020.1746265. View

12.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

13.

Mazieres J, Cropet C, Montane L, Barlesi F, Souquet P, Quantin X . Vemurafenib in non-small-cell lung cancer patients with BRAF and BRAF mutations. Ann Oncol. 2020; 31(2):289-294. DOI: 10.1016/j.annonc.2019.10.022. View

14.

Riely G, Smit E, Ahn M, Felip E, Ramalingam S, Tsao A . Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With -Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023; 41(21):3700-3711. DOI: 10.1200/JCO.23.00774. View

15.

Augustyn K, Joseph J, Patel A, Razmandi A, Ali A, Tawbi H . Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice. Melanoma Res. 2023; 33(5):406-416. PMC: 10470431. DOI: 10.1097/CMR.0000000000000891. View

16.

Abdayem P, Planchard D . Ongoing progress in BRAF-mutated non-small cell lung cancer. Clin Adv Hematol Oncol. 2022; 20(11):662-672. View

17.

Bhandari N, Hess L, He D, Peterson P . Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Using a Real-World Database. J Natl Compr Canc Netw. 2023; 21(9):934-944.e1. DOI: 10.6004/jnccn.2023.7039. View

18.

Koelblinger P, Thuerigen O, Dummer R . Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018; 30(2):125-133. PMC: 5815646. DOI: 10.1097/CCO.0000000000000426. View

19.

Barlesi F, Mazieres J, Merlio J, Debieuvre D, Mosser J, Lena H . Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016; 387(10026):1415-1426. DOI: 10.1016/S0140-6736(16)00004-0. View

20.

Yaeger R, Corcoran R . Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019; 9(3):329-341. PMC: 6397699. DOI: 10.1158/2159-8290.CD-18-1321. View